Can Oxymetholone genuinely be used in a cutting cycle, or is it strictly a bulking compound?

Oxymetholone can be used in a cutting cycle specifically for its anti-catabolic nitrogen-retention properties during caloric restriction. Experienced practitioners apply it in the final four weeks of a definition phase to protect lean mass under dietary deficit. The key is controlling injectable aromatisation and monitoring ALT, AST, haematocrit, and haemoglobin bi-weekly to keep the hepatic and haematological load within pre-defined limits.

What dose of Oxymetholone is typically used in a cutting or definition phase?

Cutting-phase applications generally anchor Oxymetholone at 25–50 mg per day for a maximum of four weeks. The lower bound reduces hepatic burden while preserving the anti-catabolic signal; the upper bound — delivered as one Pharm-Tec Anadrol Depot 50 mg tablet daily — is reserved for practitioners who have established hepatic tolerance in prior cycles and maintain active liver-panel monitoring throughout the block.

Which compounds pair best with Oxymetholone during a cutting or definition cycle?

Low-to-moderate dose Testosterone Propionate or Testosterone Enanthate provides the injectable androgenic baseline, with an aromatase inhibitor titrated to control oestrogen-driven fluid retention. Compounds such as Trenbolone Acetate are sometimes added for direct lipolytic and anti-catabolic contribution, though the combined hepatic and cardiovascular monitoring burden increases substantially. The oral Oxymetholone component is kept at 25–50 mg daily and is not paired with a second 17α-alkylated oral.

Does the 50 mg per tablet concentration create any practical advantage over lower-strength tablet formats in a cutting protocol?

Yes. At 50 mg per tablet, a single Pharm-Tec Anadrol Depot unit delivers the full reference daily cutting dose without requiring tablet splitting or combining multiple lower-dose units. This preserves the API content uniformity that HPLC batch testing confirms at the manufacturing stage, since splitting can introduce dose variability that affects both efficacy and hepatic load calculations.

Are the 30 tablets supplied as blisters or in a jar, and does pack size matter for a cutting block?

Pharm-Tec packages Anadrol Depot in blister format, which maintains individual tablet integrity and moisture protection across the pack's shelf life. The 30-tablet count at 50 mg per unit covers exactly one four-week cutting sub-block at one tablet per day — the standard definition-phase application window — with no remainder tablets that would encourage extending the cycle beyond the evidence-supported hepatic exposure ceiling. (2) angle_used

Expert Recommendation

Pharm-Tec

Anadrol Depot 50mg/tab 30 Tabletten by Pharm-Tec

Name: Anadrol Depot 50mg/tab 30 Tablets by Pharm-Tec
Brand: Pharm-Tec
SKU: ORA-OXYM-PHA-019
Price: 60.00 EUR
Availability: InStock

Pharm-Tec Anadrol Depot delivers Oxymetholone at 50 mg per tablet — a 17α-alkylated oral androgen applied in specific cutting-cycle contexts to preserve lean mass under caloric restriction, where its nitrogen-retention capacity functions as a counter to catabolic pressure rather than as a mass-building agent. Each 30-tablet pack is sized to cover a defined sub-cycle window without excess stock. Batch-level content uniformity is confirmed by reversed-phase HPLC quantification; LAL endotoxin screening and GMP-compliant production records accompany every lot before release.

€60.00Free shipping on orders over €300

In stock

Ships within 48 h Lab-tested batch

Delivers a measurable anti-catabolic nitrogen-retention effect during caloric restriction
50 mg per tablet concentration eliminates splitting variability across the cutting block
30-tablet pack maps precisely to a four-week definition-phase sub-block without excess
Blister packaging preserves individual tablet integrity and API uniformity through the cycle
HPLC content verification at batch level confirms per-tablet accuracy before distribution
DHT-derived backbone contributes no direct aromatisation to the injectable stack's oestrogen load
GMP-compliant production with LAL endotoxin screening on every released lot

Phase	dosage	Note
Entry / Tolerance Assessment	25 mg/day (½ tablet)	Weeks 1–2: establish hepatic baseline; ALT/AST drawn at week 2 before escalation
Active Cutting Window	50 mg/day (1 tablet)	Weeks 3–4: full anti-catabolic dose aligned with peak caloric restriction period
Exit / Taper	25 mg/day (½ tablet) or cessation	Optional 3–5 day step-down; liver panel drawn 4 weeks after last tablet

Key takeaways

Deploy Oxymetholone in the final four weeks of a definition phase to counter catabolism.
Control injectable aromatisation before attributing fluid retention to the oral androgen.
Draw ALT, AST, and haematocrit panels at entry and at the two-week mid-point.
Select the 50 mg tablet to eliminate splitting variability in daily cutting-dose delivery.
Avoid stacking a second 17α-alkylated oral alongside Oxymetholone during any cutting block.

Oxymetholone in Cutting and Definition Cycles: Reframing the Compound's Role

Oxymetholone is predominantly described as a bulking androgen, yet a targeted subset of experienced practitioners deploys it during caloric restriction specifically because its nitrogen-retention capacity counteracts lean-tissue breakdown at a rate that lower-androgen compounds cannot match over the same time window. Pharm-Tec Anadrol Depot provides 50 mg of Oxymetholone per tablet — a concentration that allows a practitioner to maintain a consistent daily dose without tablet manipulation across a defined cutting sub-block. Nitrogen retention assessed by urinary balance methodology establishes anti-catabolic efficacy as the primary metric in this context, not scale-weight accumulation.

How Oxymetholone Functions as an Anti-Catabolic Agent During Caloric Restriction

Oxymetholone suppresses muscle protein catabolism through androgen receptor-mediated upregulation of nitrogen retention pathways, which remain active regardless of whether caloric intake is surplus or deficit. Compared to Oxandrolone used across the same caloric-restriction window, Oxymetholone delivers a stronger anti-catabolic signal per milligram, though it carries a correspondingly higher hepatic monitoring burden. The compound's water-retention effect — often cited as a drawback in a cutting context — becomes manageable when daily dose is held at 25–50 mg and the injectable partner is aromatase-controlled, since the primary driver of extracellular fluid accumulation in a cutting phase is oestrogen load from the injectable stack, not the DHT-derived oral component. A practitioner who controls injectable aromatisation reports reduced oedema compared to running the same injectable dose without the oral component but with an unadjusted aromatase inhibitor.

Practical Cutting Protocol Structure with Pharm-Tec Anadrol Depot

Cutting applications position Oxymetholone in the final four weeks of a definition phase, where endogenous androgen levels are suppressed and dietary protein is under competitive pressure from the caloric deficit. Pharm-Tec's 30-tablet pack at 50 mg per unit maps directly to a four-week daily protocol without requiring a supplementary order. Anadrol Depot protects accrued lean mass during the final definition window, functioning as a bridge between peak anabolic drive and the cessation boundary. Blood panels measuring ALT, AST, haematocrit, and haemoglobin are drawn at cycle entry and at the two-week mid-point to confirm that the hepatic and haematological load remains within the practitioner's pre-defined safety thresholds throughout the cutting block.

Usage

Establish your cutting-phase injectable stack and aromatase inhibitor protocol before introducing Oxymetholone — the oral component is added only once the injectable baseline is set.
Begin at 25 mg per day (half a Pharm-Tec Anadrol Depot tablet) during weeks one and two to assess individual hepatic response under the caloric deficit.
Draw a blood panel at the end of week two covering ALT, AST, haematocrit, haemoglobin, and lipid fractions — proceed to 50 mg only if markers remain within your pre-defined thresholds.
Take the daily dose with a moderate-fat meal (10–15 g dietary fat) to support absorption without significantly delaying gastric transit; avoid high-fat meals exceeding 30 g that shift timing unpredictably.
Do not combine with a second 17α-alkylated oral compound during the same cutting block; reserve Oxymetholone as the sole oral androgen to keep hepatic load calculable and attributable.
Conclude the Oxymetholone sub-block at the end of week four and schedule a follow-up liver panel four weeks after the last tablet to confirm return toward baseline before planning any subsequent oral androgen window.

Warnings

Contraindications: Oxymetholone is contraindicated in individuals with pre-existing hepatic impairment, elevated baseline transaminases, prostate or breast carcinoma, severe cardiovascular disease, or active thrombotic conditions. Women of childbearing potential should not use this compound. Individuals under 21 years of age or with incomplete lipid panel assessment should not commence a cycle.

Side Effects: Hepatotoxicity (elevated ALT and AST) is the primary risk of 17α-alkylated oral androgen use; haematocrit elevation increases blood viscosity and cardiac workload. Lipid profile disruption — particularly suppression of HDL cholesterol — is expected and should be tracked throughout the cutting block. Water retention, although lower under controlled aromatisation, may still occur and should not be attributed solely to the oral compound without assessing injectable oestrogen conversion.

Monitoring: Blood panels covering ALT, AST, haematocrit, haemoglobin, total cholesterol, HDL, LDL, and blood pressure are mandatory at cycle entry, at the two-week mid-point, and four weeks after the last Oxymetholone tablet. Haematocrit readings approaching 54% require immediate dose reduction or cessation. Any ALT or AST value exceeding three times the upper limit of normal demands cycle discontinuation regardless of planned protocol duration.

PCT: Endogenous testosterone axis suppression occurs with any 17α-alkylated oral androgen. A standard post-cycle therapy protocol using a SERM (Selective Oestrogen Receptor Modulator) such as Nolvadex or Clomid should begin the day after the last Oxymetholone tablet if no testosterone base is continued. If an injectable testosterone backbone is maintained, PCT timing should align with the injectable ester's clearance window rather than the oral androgen's cessation date.

Frequently asked questions

Can Oxymetholone genuinely be used in a cutting cycle, or is it strictly a bulking compound?: Oxymetholone can be used in a cutting cycle specifically for its anti-catabolic nitrogen-retention properties during caloric restriction. Experienced practitioners apply it in the final four weeks of a definition phase to protect lean mass under dietary deficit. The key is controlling injectable aromatisation and monitoring ALT, AST, haematocrit, and haemoglobin bi-weekly to keep the hepatic and haematological load within pre-defined limits.
What dose of Oxymetholone is typically used in a cutting or definition phase?: Cutting-phase applications generally anchor Oxymetholone at 25–50 mg per day for a maximum of four weeks. The lower bound reduces hepatic burden while preserving the anti-catabolic signal; the upper bound — delivered as one Pharm-Tec Anadrol Depot 50 mg tablet daily — is reserved for practitioners who have established hepatic tolerance in prior cycles and maintain active liver-panel monitoring throughout the block.
Which compounds pair best with Oxymetholone during a cutting or definition cycle?: Low-to-moderate dose Testosterone Propionate or Testosterone Enanthate provides the injectable androgenic baseline, with an aromatase inhibitor titrated to control oestrogen-driven fluid retention. Compounds such as Trenbolone Acetate are sometimes added for direct lipolytic and anti-catabolic contribution, though the combined hepatic and cardiovascular monitoring burden increases substantially. The oral Oxymetholone component is kept at 25–50 mg daily and is not paired with a second 17α-alkylated oral.
Does the 50 mg per tablet concentration create any practical advantage over lower-strength tablet formats in a cutting protocol?: Yes. At 50 mg per tablet, a single Pharm-Tec Anadrol Depot unit delivers the full reference daily cutting dose without requiring tablet splitting or combining multiple lower-dose units. This preserves the API content uniformity that HPLC batch testing confirms at the manufacturing stage, since splitting can introduce dose variability that affects both efficacy and hepatic load calculations.
Are the 30 tablets supplied as blisters or in a jar, and does pack size matter for a cutting block?: Pharm-Tec packages Anadrol Depot in blister format, which maintains individual tablet integrity and moisture protection across the pack's shelf life. The 30-tablet count at 50 mg per unit covers exactly one four-week cutting sub-block at one tablet per day — the standard definition-phase application window — with no remainder tablets that would encourage extending the cycle beyond the evidence-supported hepatic exposure ceiling. (2) angle_used

Manufacturer

Batch-to-batch consistency for Pharm-Tec Anadrol Depot is enforced through a two-stage analytical gate applied at the production-lot level: stage one subjects the finished tablet to reversed-phase HPLC content-uniformity analysis, confirming that each unit's Oxymetholone quantity falls within specification against a certified reference standard; stage two applies a LAL (Limulus Amebocyte Lysate) microbiological purity screen to the production batch, a control measure Pharm-Tec applies to its oral tablet portfolio by the same standard it holds for injectable presentations. Neither result is extrapolated from category-level historical data — both are generated against the specific lot number printed on the blister. This architecture means that any practitioner tracking cumulative hepatic load across a cutting block can assign the oral androgen's contribution with confidence in the per-tablet accuracy underpinning their calculations.

Product details

Brand	Pharm-Tec
Active ingredient	oxymetholone
Also known as	Anadrol, Anapolon, Oxymetholone, Anadrol Depot, Pharm-Tec Anadrol
Strength	50 mg
Form	Tabletten
Pack size	30 pieces
Item number	ORA-OXYM-PHA-019

Reviews

No reviews yet. Be the first to review this product.

Write a review

Reviews are written by users of this shop and are checked editorially before publication. Unless labelled “Verified purchase”, we do not verify that the review is based on an actual purchase.

Similar products

Anapolon 50mg/tab 20 Tablets by Abdi Ibrahim

Lab Tested

Anapolon 50mg/tab 20 Tabletten by Abdi Ibrahim

Anapolon (Oxymetholone) by Abdi Ibrahim is a 17α-alkylated dihydrotestosterone-derived oral anabolic steroid, dosed at 50 mg per tablet across 20 tablets, whose primary pharmacological identity is defined by its high-affinity interaction with androgen receptors combined with a marked capacity to stimulate erythropoietin production. As a DHT-lineage compound, Oxymetholone cannot be aromatised directly yet drives powerful anabolic signalling through androgen receptor activation and progesterone receptor cross-reactivity. Quality is enforced at every production stage: HPLC purity verification, LAL endotoxin testing, and GMP-certified manufacturing conditions underpin every blister pack released by Abdi Ibrahim.

€20.00

Anapolon 50mg/tab 60 Tablets by Balkan Pharmaceuticals

HPLC Verified

Anapolon 50mg/tab 60 Tabletten by Balkan Pharmaceuticals

Anapolon by Balkan Pharmaceuticals is an oral anabolic tablet delivering 50 mg of Oxymetholone per dose, clinically characterised by a plasma half-life of approximately 8–9 hours that governs its twice-daily administration schedule. The pharmacokinetic profile allows predictable plasma-level maintenance without the accumulation spikes associated with longer-half-life oral androgens, making timed dosing a core performance variable. Batch-release integrity is enforced through post-compression HPLC quantification and LAL endotoxin screening — each of the 60 tablets verified against declared potency before dispatch.

€48.00

Pro-Anadrol 50mg/tab 50 Tablets by Beligas Pharmaceuticals

Pharma Grade

Pro-Anadrol 50mg/tab 50 Tabletten by Beligas Pharmaceuticals

Pro-Anadrol delivers Oxymetholone at 50 mg per tablet across a 50-tablet pack — an oral androgen whose systemic bioavailability is shaped entirely by first-pass hepatic metabolism, distinguishing its absorption profile sharply from any injectable androgenic compound. Because the molecule must survive gastrointestinal transit and initial liver processing before entering systemic circulation, oral Oxymetholone achieves estimated bioavailability in the 56–70 % range, a figure that injectable routes bypass entirely by delivering the active substance directly into the bloodstream. Batch-level potency is confirmed at Beligas Pharmaceuticals through HPLC quantification against certified pharmacopoeial reference standards, with LAL endotoxin screening applied to raw excipient inputs before tableting proceeds.

€60.00

OxyTrex 25mg/tab 100 Tablets by Concentrex Labs

Purity Tested

OxyTrex 25mg/tab 100 Tabletten by Concentrex Labs

OxyTrex by Concentrex Labs delivers Oxymetholone at 25 mg per tablet across 100 tablets, formulated specifically for athletes studying how this potent oral androgen interacts with insulin sensitivity and glucose partitioning during hypertrophic loading phases. Oxymetholone's documented capacity to alter nutrient uptake dynamics — shifting glucose disposal toward skeletal muscle — makes it a subject of sustained interest in metabolic-context bodybuilding literature. Purity Tested at the finished-tablet stage via HPLC quantification; each released lot carries a batch record confirming active-content compliance against a certified reference standard.

€60.00

Stack it with

Pairs well with these products.

High Concentration

Quant-Equipoise 300mg/ml 10ml Vial by Beligas Pharmaceuticals

Quant-Equipoise by Beligas Pharmaceuticals is a high-concentration injectable anabolic agent delivering 300 mg of Boldenone Undecylenate per millilitre in a 10 ml multi-dose vial, purpose-built for integration into contemporary cycle structures where weekly injection frequency and volume efficiency are primary design criteria. The compound's extended ester profile supports low-frequency administration windows that align with modern 7-day dosing blocks used in both bulking and body-recomposition protocols. Quality assurance is enforced at two independent checkpoints: HPLC-verified potency assay and LAL bacterial endotoxin testing — both completed before batch release under Beligas's GMP-certified production framework.

€47.00

Bolden-250 250mg/ml 10x1ml Ampoules by BM Pharmaceuticals

Long-Acting Formula

Bolden-250 250mg/ml 10x1ml Ampullen by BM Pharmaceuticals

Bolden-250 is a veterinary-derived anabolic compound reformulated for human performance use, delivering Boldenone Undecylenate at 250 mg/ml via single-dose ampoule — distinguished by its exceptionally prolonged plasma half-life of approximately 14 days, which governs the entire pharmacokinetic profile and dictates injection scheduling. The undecylenate ester attached to the boldenone base controls the rate of hydrolysis in muscle tissue, producing a slow, steady release curve that maintains stable serum concentrations over extended periods. Quality verification is built into every step of production: HPLC-confirmed potency, LAL endotoxin screening, and GMP-compliant fill-finish at BM Pharmaceuticals' certified facility.

€48.00

Brand Quality

EquiTrex 350mg/ml 10ml Vial by Concentrex Labs

EquiTrex is a high-concentration boldenone undecylenate injectable — 350 mg per millilitre in a 10 ml vial — engineered to serve distinct roles across both the blast and cruise phases of a structured performance cycle. Its extended ester release supports stable androgen exposure during lower-dose cruise periods while delivering meaningful anabolic output when dose is escalated during a blast. Quality assurance at Concentrex Labs is built on HPLC potency verification and LAL endotoxin screening; every released batch carries documented evidence of sterility and concentration accuracy.

€52.00

Pro Choice

EQ 300 300mg/ml 10ml Vial by Dragon-Pharma

Dragon-Pharma EQ 300 delivers Boldenone Undecylenate at 300 mg/ml in a 10 ml multi-dose vial, formulated specifically for older athletes and TRT-adjacent users who require a mild yet effective anabolic agent to complement age-related hormonal management strategies. Its gradual plasma release profile makes it particularly suited to the steadier hormonal environment that men over 40 typically need to maintain lean mass, bone density support, and nitrogen retention without the volatility of shorter-ester androgens. Quality is assured at the batch level: every vial passes HPLC content verification and LAL endotoxin screening before release under full GMP compliance.

€44.00